Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.
News
Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.
After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...
This paper highlights the transformative potential of our deep neural network, AIMLinker, in the field of drug discovery for PROTAC design...
AnHorn Medicines, as one of the innovators in the field of Targeted Protein Degradation, we have commitment to identify novel E3 enzymes with a clear disease involvement to expand our target coverage.
AnHorn Medicines participated NBRP DEMO DAY to show our one-year progress in research and make connections with investors, global pharma R&D experts, talents, and partners in this field....
We are moving forward to Artificial Intelligence Drug Discovery. The AI-enabled AIMCADD® platform helps us to identify new targets and treatments easier, and better....
AnHorn Medicines’s achievements in 2020, including the smooth establishment for research, operation and finance that support us for considerable progress in 2021...
AnHorn Medicines was established in March 2020. Dr. Lin, the founder and CEO, is the former head of drug discovery team in a well-known Taiwan biotech company...